MET and non-small cell lung carcinoma: Preclinical data and case reports suggest that MET-amplified EGFR-mutated NSCLC are addicted to both MET and EGFR and that combination of MET and EGFR TKIs is required to overcome this mechanism of resistance [9, 18, 19].